AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Recruiting participants (Starts Nov. 3, 2014)
Not accepting healthy volunteers
UTSW Principal Investigator: Tamra Lynn Slone
summary
See protocol/CiRB application
eligibility
See protocol
Participate
If you are interested in this clinical trial, please contact Princess Iroh on the Children’s Health Research Team.Call 214-590-0608Email
STU 102014-066
AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
